This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, T. M. Articles by Dubeau, L. Search for Related Content PubMed PubMed Citation Articles by Kim, T. M. Articles by Dubeau, L.

Loss of Heterozygosity on Chromosome 13 Is Common Only in the Biologically More Aggressive Subtypes of Ovarian Epithelial Tumors and Is Associated with Normal Retinoblastoma Gene Expression¹

Departments of Pathology [T. M. K., M. V., E. Y., J. Z., G. D., L. D.] and Gynecologic Oncology [J. G.], Kenneth Norris Jr. Comprehensive Cancer Center, USC School of Medicine, Los Angeles, California 90033, and Center for Biotechnology, Baylor College of Medicine, The Woodlands, Texas 77381 [W. F. B., H-J. X., S-X. H]

We examined the frequencies of loss of heterozygosity on chromosome 13 in 77 primary ovarian epithelial tumors subdivided into cystadenomas, tumors of low malignant potential, low grade carcinomas, and high grade carcinomas. Such losses were found in approximately 50% of high grade carcinomas but were not detected in any of the other tumor subtypes (P < 0.0001), suggesting a strong association between these abnormalities and the high grade carcinoma phenotype. The tumors were also examined for abnormalities in expression of the retinoblastoma susceptibility gene (RB). This was assessed by immunohistochemical staining of archival tumor sections with a polyclonal antibody directed against both the phosphorylated and the underphosphorylated forms of the RB protein. Most of the tumors, including those with allelic deletions on chromosome 13, showed normal RB nuclear protein staining patterns. We conclude that loss of RB expression is not a frequent event in primary ovarian carcinomas and that this gene is probably not the target of the frequent allelic deletions on chromosome 13 found in high grade ovarian carcinomas.

¹ This work was aided by Grants R29 CA51167, R01 CA60443, and R01 CA54672 from the National Cancer Institute and by Grant EDT-11B from the American Cancer Society.

² To whom requests for reprints should be addressed, at Kenneth Norris Jr. Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033.

Received 10/ 7/93. Accepted 12/17/93.

This article has been cited by other articles:

				A P M Jongsma, J M J Piek, R P Zweemer, R H M Verheijen, J W T Klein Gebbinck, G J van Kamp, I J Jacobs, P Shaw, P J van Diest, and P Kenemans Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer Mol. Pathol., October 1, 2002; 55(5): 305 - 309. [Abstract] [Full Text] [PDF]

				A J Alvi, R Hogg, J S Rader, M J Kuo, E R Maher, and F Latif Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer Mol. Pathol., June 1, 2002; 55(3): 153 - 155. [Abstract] [Full Text] [PDF]

				T. Kusume, H. Tsuda, M. Kawabata, T. Inoue, N. Umesaki, T. Suzuki, and K. Yamamoto The p16-Cyclin D1/CDK4-pRb Pathway and Clinical Outcome in Epithelial Ovarian Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4152 - 4157. [Abstract] [Full Text] [PDF]

				D. J. Simpson, J. Magnay, J. E. Bicknell, A. L. Barkan, A. M. McNicol, R. N. Clayton, and W. E. Farrell Chromosome 13q Deletion Mapping in Pituitary Tumors: Infrequent Loss of the Retinoblastoma Susceptibility Gene (RB1) Locus Despite Loss of RB1 Protein Product in Somatotrophinomas Cancer Res., April 1, 1999; 59(7): 1562 - 1566. [Abstract] [Full Text] [PDF]